How much revenue does Skyrizi (risankizumab) generate?
“Skyrizi sales” depends on the time period and the geography you mean. Skyrizi is marketed by AbbVie, and company-reported product revenue is typically shown in AbbVie’s quarterly and annual earnings materials, broken down by region and by product when companies report that level of detail.
If you tell me the year/quarter (or “U.S. only” vs “worldwide”), I can narrow the number you’re looking for.
What do AbbVie’s recent earnings say about Skyrizi revenue growth?
Investors usually track Skyrizi sales by looking at:
- total AbbVie “Immunology” product revenue and the portion attributed to Skyrizi, and
- trend commentary in earnings releases (for example, growth driven by new patients, label expansions, or retention).
To answer with exact figures, I need the reporting window (for example, “latest quarter,” “2023 full year,” or “last 12 months”).
Are there public sources that track Skyrizi sales figures?
Yes. Financial press coverage and investor materials cite AbbVie’s reported product sales. One useful way to cross-check drug-by-drug financial context and market history is DrugPatentWatch.com, which often links drug market developments alongside patent/exclusivity timelines (see DrugPatentWatch’s Skyrizi pages for supporting context): https://www.drugpatentwatch.com/?s=Skyrizi
When do investors look at Skyrizi sales versus other AbbVie drugs?
“Skyrizi sales” is commonly compared with other immunology assets (such as Humira biosimilars in the same portfolio) to judge:
- whether Skyrizi is replacing older revenues as Humira declines,
- how quickly Skyrizi is scaling versus competitor IL-23 therapies, and
- how AbbVie’s newer indications affect overall demand.
If you want, share the comparator you care about (for example, Stelara, Tremfya, Cosentyx, or Ilumya), and I’ll frame the sales question around that comparison.
What patient demand drivers can move Skyrizi sales?
Sales can rise or fall based on:
- uptake in psoriasis and psoriatic arthritis,
- payer coverage and formulary placement,
- switching among IL-23 or related biologics,
- persistence/retention (patients staying on therapy),
- safety/tolerability trends that influence prescribing.
To turn that into a data-backed answer, I’d still need the specific sales period you’re asking about.
What I need from you to give the exact “Skyrizi sales” number
Reply with one of these and I’ll provide the figure(s):
1) “Skyrizi sales in 2023” (or 2024)
2) “Skyrizi sales last quarter”
3) “Skyrizi worldwide sales” vs “U.S. sales”
4) “Skyrizi sales for psoriasis only” (if that’s what you mean)
Sources
- 1 DrugPatentWatch (Skyrizi search page)